Atiprimod

Drugbox
IUPAC_name = 3-(8,8-dipropyl-3-azaspiro [4.5] decan-3-yl)-"N","N"- diethylpropan-1-amine

---

CAS_number = 123018-47-3
ATC_prefix =
ATC_suffix =
PubChem = 129869
DrugBank =
C=22 |H=44 |N=2
molecular_weight = 336.598 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Atiprimod (INN, codenamed SK&F106615; also known as azaspirane, although this more properly refers to the class of chemicals to which atiprimod belongs) is a substance being studied in the treatment of certain multiple myelomas and other advanced cancers. Atiprimod may block the growth of tumors and the growth of blood vessels from surrounding tissue to the tumor. Atiprimod is a type of signal transduction inhibitor. It was first developed by SmithKline Beecham (now part of GlaxoSmithKline) as a potential treatment for rheumatoid arthritis. [cite journal |url=http://myeloma.org/main.jsp?type=article&id=1379 |title=Atiprimod: A New Drug Candidate in Early-Stage Development for Myeloma |author=Jacobs GS |journal=Myeloma Today |date=Spring 2004 |volume=5 |issue=10 |publisher=International Myeloma Foundation Retrieved on September 14, 200.]

References

Further reading

*cite journal |author=Hamasaki M, Hideshima T, Tassone P, "et al" |title=Azaspirane ("N"-"N"-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo |journal=Blood |volume=105 |issue=11 |pages=4470–6 |year=2005 |month=June |pmid=15705788 |doi=10.1182/blood-2004-09-3794 PMC|1895034

External links

* [http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=486451 Atiprimod] entry in the public domain NCI Dictionary of Cancer Terms